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Lentiviral vectors pseudotyped with the envelope glycoproteins (Env) of amphotropic murine leukemia virus (MLV) and the
G protein of vesicular stomatitis virus (VSV-G) have been successfully used in recent preclinical gene therapy studies. We
report here the generation of infectious HIV-1-derived vector particles pseudotyped with the Env of the molecular clone 10A1
of MLV and with chimeric envelope glycoprotein variants derived from gibbon ape leukemia virus (GaLV) and MLV. Formation
of infectious HIV-1 (GaLV) pseudotype vectors was only possible with the substitution of the cytoplasmic tail of GaLV Env with
that of MLV. The lentiviral vectors exhibited a host cell range identical with that of MLV(GaLV) and MLV(10A1) vectors, which
are known to enter cells either via the GaLV-receptor Glvr-1 (Pit-1) or via the amphotropic receptor Ram-1 (Pit-2) in addition
to Glvr-1, respectively. Thus, HIV-1(GaLV) and HIV-1(10A1) pseudotype vectors may be useful for efficient gene transfer into
a variety of human tissues like primary human hematopoietic cells. © 2000 Academic PressKey Words: lentiviral vector; pseudotype vector; GaLV Env; 10A1 Env.
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gMurine leukemia virus (MLV)-derived vectors
pseudotyped with the envelope glycoproteins (Env) of the
molecular MLV clone 10A1 (MLV-10A1) or those of gib-
bon ape leukemia virus (GaLV) have been shown to
allow efficient gene transfer into a variety of human cells
including human CD34-positive cells and peripheral
blood leukocytes (PBLs) (1, 2). Human CD34-positive
ells, more specifically the hematopoietic stem cells
HSCs) contained within this cell population, and PBLs
re less susceptible to transduction by amphotropic MLV
MLV-A) vectors, most likely due to the low cell surface
xpression of the amphotropic MLV receptor Ram-1 (3).
LV vector particles harboring the GaLV Env or the 10A1
nv have been shown to more efficiently transduce hu-
an CD34-positive cells and PBLs. One of the presumed
easons for the improved gene transfer efficiency is the
sage of the GaLV receptor Glvr-1 by MLV(GaLV) and the
sage of either Glvr-1 or Ram-1 by MLV(10A1) (4). How-
ver, MLV-derived vectors allow transduction of prolifer-
ting target cells only. In contrast, lentiviral vectors, e.g.,
hose derived from HIV-1, have been used for efficient
ene transfer into resting or slowly dividing human cells.
n this respect lentiviral vectors are superior to onco-
etroviral vectors (5). As the natural tropism of HIV-1 is
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16estricted to CD41 cells, HIV-1 vectors are usually
seudotyped with VSV-G or the amphotropic MLV Env in
rder to broaden their target cell range (6). We have now
uccessfully generated HIV-1-derived pseudotype vector
articles harboring the 10A1 Env or a C-terminally mod-
fied GaLV Env. The modified GaLV Env encompassed
he surface envelope glycoprotein (SU) of GaLV and a
himeric transmembrane (TM) protein derived from GaLV
nd from MLV-A. The resulting HIV-1(GaLV) and HIV-
(10A1) vector particles have been shown to exhibit the
ell tropism of GaLV and MLV-10A1, respectively. They
ay be useful for improving gene transfer efficiency into
mportant target cells of gene therapy such as human
SCs and PBLs.
Results and Discussion. Generation of HIV-1
seudotype vector particles using MLV-10A1 Env, but not
ild- type GaLV Env. To investigate pseudotype formation
f HIV-1 with GaLV and MLV-10A1, suitable env expres-
ion genes were constructed. The complete coding re-
ions of the wild-type env genes from MLV-A, GaLV, and
LV-10A1 were inserted into the expression construct of
lasmid pALF (7) comprising the FB29 Friend murine
eukemia virus (FLV) promoter and the poly(A) signal
equence of the human phosphoglycerate kinase gene
Fig. 1A). Two days after transfection of 293T cells with all
hree constructs, Env expression was demonstrated by
mmunostaining of cells using a serum directed against
p71-SU of FLV (Fig. 2A, a–d). In order to generate HIV-1
ector particles, 293T cells were cotransfected with the
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17RAPID COMMUNICATIONpackaging construct CMVDR8.2 encoding HIV-1 gag/pol,
the packaging signal-positive transfer vector HR9CMV-
acZ encoding b-Gal (8), and one of the respective env-
xpression constructs. MLV(MLV-A) vector particles
ere generated by transfecting the packaging construct
IT60 and the transfer vector construct HIT111 (9) and
erved as positive controls. As a negative control 293T
ells were transfected with the respective packaging
onstructs and transfer vectors in the absence of an env
ene construct. In order to assay transduction of cells,
upernatants of the transfected cells harvested 2 days
fter transfection were incubated with human HT1080
ibrosarcoma cells (Ram-11/Glvr-11), canine D17 osteo-
arcoma cells (Ram-11/Glvr-11), and murine NIH-3T3
ibroblasts (Ram-11/Glvr-12) as described under Mate-
ials and Methods. Two days later, transduction was
onitored by X-Gal staining of b-Gal-expressing cells.
ene transfer efficiency was determined as described
reviously (10). As shown in Table 1, infectious MLV
seudotype vector particles were generated with all
hree env gene constructs. As expected, they showed the
arget cell range of the viruses from which each respec-
ive Env was derived. No gene transfer was detectable
ollowing transfection of the relevant packaging and
FIG. 1. Schematic diagram of the env gene constructs. (A) All env g
7) containing the LTR of FB29 strain of Friend MLV. A phleomycin-resist
f the LTR of Friend MLV C57. (B) Amino acid sequence alignment of th
lycoproteins (TM) encoded by the env gene constructs. Sequences s
egions derived from MLV-10A1 and GaLV, respectively.ransfer constructs in the absence of any viral env gene odata not shown). Similar to HIV-1 (MLV-A), efficient gen-
ration of infectious HIV-1(10A1) vector particles was
etected. However, no HIV vector-mediated transduction
as detected using the wild-type GaLV Env (GaLV wt
nv). It was concluded either that GaLV wt Env incorpo-
ation was insufficient for the formation of infectious
IV-1 (GaLV wt) vector particles or that the resulting
seudotype vectors harboring GaLV wt Env were not
nfectious.
Construction of chimeric env genes derived from GaLV
nd MLV-A. To allow formation of infectious retroviral
ector particles the proteins used to form the vector
nvelope must be efficiently incorporated by the viral
apsid particles. Once incorporated, they also must me-
iate binding of the resulting vector particles to a suit-
ble cell surface receptor, fusion of the viral and cellular
embrane, and entry into the cytoplasm. As we had
bserved that wild-type GaLV Env, although allowing the
eneration of infectious MLV pseudotype vectors, appar-
ntly did not efficiently mediate formation of infectious
IV-1 pseudotype vector particles, we assumed that this
as caused by inefficient incorporation and/or low fusio-
enicity. The C-tail of TM has been reported to influence
nv incorporation of various retroviruses (11, 12). On the
scribed here were molecularly cloned into expression construct ALF
ene (phleo) located downstream of the env gene was under the control
ctive transmembrane regions (TMR) and C-tails of the transmembrane
in gray were derived from MLV-A; light gray and open boxes indicateenes de
ance g
e respe
hadedther hand, cellular and viral transmembrane proteins
i
o
18 RAPID COMMUNICATIONhave been shown to be efficiently incorporated by HIV-1
virions independent of any C-terminal modifications
(13, 14). Moreover, the C-terminal domain following the
transmembrane-spanning region (C-tail) of retroviral TM
has been shown to trigger the fusion capacity of Env. For
example, the C-tail of MLV TM is processed by the viral
protease during virion maturation. Cleavage of a small
peptide (R-peptide) of 16 amino acids from the TM C-
FIG. 2. Expression of the envelope proteins in transfected 293T cells
performed as described under Materials and Methods: (a) mock; (b) M
Env. (B) Detection of the indicated Env on the cell surface by FACS us
phycoerythrin.
TABLE 1
Infectivity of Vector Particles Pseudotyped
with Retroviral Envelope Proteins
Vector particle
Target cellsa
HT1080 D17 3T3
MLV(MLV-A) 1.0 3 105 1.2 3 105 1.3 3 105
MLV(10A1) 8.2 3 104 1.0 3 104 4.5 3 104
MLV(GaLV wt) 2.5 3 105 2.8 3 105 ,101
HIV(MLV-A) 2.7 3 104 2.3 3 103 1.0 3 103
HIV(10A1) 5.0 3 104 9.0 3 103 6.0 3 102
HIV(GaLV wt) ,101 ,101 ,101
a MLV and HIV-1 pseudotype vectors were titrated on the target cells
ndicated. Titers are reported as lacZ i.u./ml. Data shown resulted from
ne representative experiment of three.terminus results in vastly enhanced fusiogenicity of the
Env (15). MLV-A Env efficiently confers infectivity to HIV-1
pseudotype vectors and has been demonstrated to be
processed by the HIV-1 protease (16). We therefore
tested whether a substitution of the C-terminal amino
acids of GaLV TM by those of MLV TM would allow the
formation of infectious HIV-1 vector particles. First, we
constructed chimeric env genes comprising the gp71-SU
coding region of GaLV and the N-terminal region of the
GaLV TM except for the C-terminal amino acids and/or
the transmembrane region (TMR), which were replaced
by those of the MLV TM. The chimeric env gene coding
regions were generated by PCR and fusion-PCR, respec-
tively, and inserted into the env expression construct ALF.
As shown in Fig. 1B, in Env-variant GaLV TM the TMR
and the C-terminal amino acids following the TMR were
replaced by those of the MLV TM. The env gene product
GaLV CM encompassed only the C-tail of the MLV TM,
whereas all other GaLV TM coding regions were re-
tained. After transfection of constructs pALF-GaLV TM
and pALF-GaLV CM into 293T cells, Env expression was
demonstrated by immunostaining as described above
(Fig. 2A, e and f). To demonstrate the functional expres-
sion and presence on the cell surface of the packaging
cells, the transfected cells were stained with anti-FLV
sing an antiserum directed against FLV gp71-SU immunostaining was
nv; (c) MLV-10A1 Env; (d) GaLV wt Env; (e) GaLV CM Env; (f) GaLV TM
anti-FLV gp71-SU serum and secondary antibodies conjugated with. (A) U
LV-A E
ing thegp71-SU antibodies and phycoerythrin-labeled second-
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19RAPID COMMUNICATIONary antibodies and subsequently subjected to fluores-
cence activated cell sorting (FACS). Cells transfected
with either the MLV-A or the GaLV wt env genes served
as positive controls, whereas mock-transfected cells
were used as negative controls. As shown in Fig. 2B, all
Env variants were expressed on the surface of the trans-
fected 293T cells.
Chimeric Env variants GaLV TM and GaLV CM allow
efficient formation of infectious HIV-1 pseudotype vectors
exhibiting the target cell range of GaLV. To investigate
the potential of the chimeric Env variants GaLV TM and
GaLV CM to confer infectivity to HIV-1 and MLV cotrans-
fection of 293T cells, vector harvesting and transduction
of human HT1080, canine D17, and murine NIH-3T3 cells
were performed as described above. As shown in Table
2, both chimeric envelopes allowed the formation of
infectious MLV vector particles and were able to mediate
infectivity in HT1080 and D17 cells (Glvr-11), but not
NIH-3T3 cells (Glvr-12), as expected for envelopes har-
boring the GaLV gp71-SU. The vector titers measured
were approximately twofold (GaLV TM) and fourfold
(GaLV CM) lower than those measured after transfection
of GaLV wt Env in conjunction with the relevant packag-
ing and transfer constructs. More importantly, and in
contrast to the GaLV wt Env, only GaLV CM and GaLV TM
mediated formation of infectious HIV-1 pseudotype vec-
tor particles. HIV-1(GaLV TM) vector particles seemed to
be slightly more efficiently generated, as titers of about
1.0 3 104 infectious units per milliliter (i.u./ml) were ob-
tained. However, both pseudotype vector particles exhib-
ited the host cell range of MLV(GaLV wt) pseudotype
vector particles, indicating the usage of Glvr-1 for cell
entry as expected. In addition, and in contrast to MLV-
based vectors, HIV-1-derived vectors pseudotyped with
Env of MLV-A, GaLV TM, GaLV CM, and MLV-10A1 were
able to efficiently transduce growth-arrested HT1080 cul-
TABLE 2
Infectivity of Vector Particles Pseudotyped with Chimeric Envelope
Proteins Derived from MLV and GaLV
Vector particle
Target cellsa
HT1080 D17 3T3
MLV(MLV-A) 3.1 3 105 3.0 3 105 3.1 3 105
MLV(GaLV wt) 2.4 3 105 2.9 3 105 ,101
MLV(GaLV CM) 5.6 3 104 5.3 3 104 ,101
MLV(GaLV TM) 1.3 3 105 9.3 3 104 ,101
HIV(MLV-A) 8.3 3 104 4.4 3 103 1.5 3 103
HIV(GaLV wt) ,101 ,101 ,101
HIV(GaLV CM) 9.3 3 103 7.3 3 103 ,101
HIV(GaLV TM) 1.6 3 104 1.1 3 104 ,101
a MLV and HIV-1 pseudotype vectors were titrated on the target cells
ndicated. Titers are reported as lacZ i.u./ml. Data shown resulted from
ne representative experiment of three.tured in the presence of the DNA-polymerase inhibitor 3aphidicolin [(20 mg/ml), data not shown]. Thus, substitu-
tion of the C-terminal domain of GaLV TM by that of MLV
TM was shown to be sufficient to overcome the inability
of the GaLV wt Env to mediate formation of infectious
HIV-1 pseudotype vector particles. Additional substitu-
tion of the GaLV TM TMR by that of MLV led to a slight
additional increase of vector titers. Whether this is due to
more efficient incorporation of the chimeric GaLV-derived
Env into HI virions and/or processing of the respective
TM protein that may have resulted in enhanced fusioge-
nicity of Env remains unclear and is currently under
investigation. However, the ability to target HIV-1 vector
particles to the cell surface receptor Glvr-1 by
pseudotyping with Env of MLV-10A1 and Env variants
GaLV CM or GaLV TM offers the opportunity to further
enhance gene transfer into resting or slowly dividing
human cells. In particular, human PBLs and HSCs are
attractive targets for lentiviral gene transfer in future
gene therapy scenarios, e.g., for the treatment of immune
dysfunctions such as severe combined immunodefi-
ciency, T-cell lymphomas, or AIDS.
Materials and Methods. Cloning of retroviral env
genes. Plasmid pHIT456 (9) encoding the MLV-A env
gene [molecular clone 4070A (18)] was digested with
XbaI and ClaI. The Env encoding gene fragment was
isolated and inserted into the backbone of plasmid
pALF-PERV A (kindly donated by Y. Takeuchi, Chester
Beatty Laboratories, London, UK), thus replacing the
porcine endogenous retrovirus (PERV) env gene cod-
ng region that is followed by the C-tail encoding
equence of MLV. The env gene coding region of
LV-10A1 (GenBank Accession No. M33470) was am-
lified by PCR using DNA of plasmid pcDNA3.1 10A1
nv as a template and the oligonucleotide primers
0A1envXba1, 59-GCTCTAGAATGGAAGGTCCAGCGT-
CTCA-39, and 10A1envXba2, 59-GCTCTAGATCATG-
CTCGTACTCTATAGG-39. The resulting DNA fragment
as also digested with XbaI and ClaI and inserted into
he backbone fragment of plasmid pALF-PERV A as
escribed above. For the construction of the GaLV wt
nv expression gene, we used plasmid pMOV-GaLV
17) as the template for PCR and the oligonucleotide
rimers GaLVenvXba1, 59-GCTCTAGAATGGTATTGCT-
CCTGGGTCC-39, and GaLVwtCla2, 59CCATCGATT-
AAAGGTTACCTTCGTTCTC-39. GaLV CM env was
onstructed using the primer GaLVwtXba1 and the
rimer GaLVTMR/Cla2-, 59-GACCAAATCGATTGAT-
ATGCATGGCCC-39. To generate the env gene variant
GaLV TM, two fragments were amplified using (i)
pMOV-GaLV and the primers GaLVenvXba1 and
FUTMR2, 59-GGTGGTAAACCAGGGGAGGTATTGAAC-
CATCC-39, and (ii) pHIT456 and the primers FUTMR1,
59-GGATGGTTCAATACCTCCCCCTGGTTTACCACC-39 and
LV-AXba2, 59-GCTCTAGATCATGGCTCGTACTCTATGGG-
9. The resulting env gene fragments were then
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20 RAPID COMMUNICATIONassembled by fusion-PCR as described previously
(19).
Cells, transfections, and infections. HT1080 human fi-
brosarcoma (ATCC CCL121) and D17 canine osteosar-
coma cells (ATCC CCL 183) were purchased from the
American Tissue Culture Collection. These cells as well
as murine NIH-3T3 fibroblasts and human kidney 293T
cells were cultured in high glucose (4.5 g/liter) DMEM
(Gibco, Eggenstein, Germany) supplemented with 10%
fetal calf serum (FCS; Biochrom, Berlin, Germany). Trans-
fection of 293T cells was performed using a total amount
of 3 mg plasmid DNA (1 mg of each plasmid encoding
one of the vector components) and the transfection re-
agent Lipofectamin Plus (Gibco) according to the manu-
facturer’s instructions. Contaminating packaging cells
were removed from the vector particle containing super-
natants by passage through a 0.45-mm filter. The super-
atants were then used in various dilutions for the trans-
uction of 1 3 105 target cells seeded in 12-well dishes
(Nunc, Wiesbaden, Germany) 24 h prior to infection.
Polybrene (10 mg/ml; Sigma, Deisenhofen, Germany) was
dded to the target cells during incubation with the
ector particles. After 2 h target cells were washed with
BS and expanded for another 2 days before being
ubjected to X-Gal staining as described previously (10).
mmunostaining and analysis by FACS.
Two days posttransfection Env-expressing cells were
ubjected to immunostaining as described elsewhere
10) using a goat anti-FLV gp71-SU serum (kind donation
f H. Schwarz, Max-Planck-Institut, Tu¨bingen, Germany)
iluted 1:400 in PBS/1% BSA and 1:1000 diluted peroxi-
ase-coupled protein G (Sigma). For FACS analysis 5 3
05 transfected cells were washed with PBA (PBS with
% FCS and 0.1% sodium azide) and incubated with the
nti-gp71-SU serum dilution for 1 h at 4°C. Cells were
hen washed twice with PBA and incubated at 4°C for 45
in with 1:40 diluted phyocoerythrin-labeled secondary
ntibodies directed against goat IgG (Sigma). After being
ashed twice with PBA, cells were subjected to FACS
nalysis (FACScan, Becton Dickinson, San Jose, CA).
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